About tremelimumab
CTLA-4 blocking monoclonal antibody
Used for
- Used with durvalumab for certain adults with unresectable liver cancer.
- Used with durvalumab and platinum chemotherapy for certain adults with metastatic non-small-cell lung cancer.
Usual adult dose
Liver cancer: 300 mg once with durvalumab, then durvalumab alone. Lung cancer: 75 mg every three weeks with durvalumab and chemotherapy, for up to five doses.
Common side effects
- Rash or itching
- Diarrhea
- Fatigue
- Liver enzyme changes
Important warnings
- Can cause serious immune-related inflammation affecting organs such as the lungs, bowel, liver, kidneys, or hormone glands.
- Treatment may need to be withheld or stopped for severe immune reactions.
- Infusion reactions can occur.
- Monitor for infection and immune complications.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for three months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for three months after the last dose.
Interactions
- No specific drug interactions are established; tell the treatment team about all medicines and supplements.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.